Beisol Pharma Kortenberg: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Beisol Pharma Kortenberg
Largest movements
- Receivables within one year -€11,366
down €11,366 (-24.1%), from €47,075 to €35,709
of which Trade receivables: -€13,450
- Other debts -€18,097
down €18,097 (-5.8%), from €311,187 to €293,090
- Profit (loss) carried forward +€12,232
up €12,232 (+15.2%), from -€80,248 to -€68,016
- Trade debts -€5,250
no longer reported in 2026 (was €5,250)
- Gross operating margin -€6,085
down €6,085 (-32.4%), from €18,778 to €12,693
- Purchases and services +€6,085
up €6,085 (+74.9%), from €8,122 to €14,207
From the 2025 result to the 2026 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2025 and 2026 balance sheets and the 2026 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2025 | 2026 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €247,855 | €236,490 | -€11,365 | -4.6% |
| Current assets | 29/58 | €247,855 | €236,490 | -€11,365 | -4.6% |
| Stocks and contracts in progress | 3 | €200,738 | €200,738 | = | 0.0% |
| Stocks | 30/36 | €200,738 | €200,738 | = | 0.0% |
| Amounts receivable within one year | 40/41 | €47,075 | €35,709 | -€11,366 | -24.1% |
| Trade receivables | 40 | €47,075 | €33,625 | -€13,450 | -28.6% |
| Other amounts receivable | 41 | - | €2,084 | +€2,084 | |
| Cash at bank and in hand | 54/58 | €42 | €43 | +€1 | +2.4% |
| Total equity and liabilities | 10/49 | €247,855 | €236,490 | -€11,365 | -4.6% |
| Equity | 10/15 | -€68,832 | -€56,600 | +€12,232 | +17.8% |
| Contributions | 10/11 | €6,200 | €6,200 | = | 0.0% |
| Capital | 10 | €6,200 | €6,200 | = | 0.0% |
| Issued capital | 100 | €18,600 | €18,600 | = | 0.0% |
| Uncalled capital | 101 | €12,400 | €12,400 | = | 0.0% |
| Reserves | 13 | €5,216 | €5,216 | = | 0.0% |
| Non-distributable reserves | 130/1 | €261 | €261 | = | 0.0% |
| Legal reserve | 130 | €261 | €261 | = | 0.0% |
| Distributable reserves | 133 | €4,955 | €4,955 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€80,248 | -€68,016 | +€12,232 | +15.2% |
| Amounts payable | 17/49 | €316,687 | €293,090 | -€23,597 | -7.5% |
| Amounts payable within one year | 42/48 | €316,687 | €293,090 | -€23,597 | -7.5% |
| Trade debts | 44 | €5,250 | - | -€5,250 | |
| Suppliers | 440/4 | €5,250 | - | -€5,250 | |
| Taxes, remuneration and social security | 45 | €250 | - | -€250 | |
| Taxes | 450/3 | €250 | - | -€250 | |
| Other amounts payable | 47/48 | €311,187 | €293,090 | -€18,097 | -5.8% |
| Turnover | 70 | €26,900 | €26,900 | = | 0.0% |
| Goods, raw materials, services and sundry goods | 60/61 | €8,122 | €14,207 | +€6,085 | +74.9% |
| Other operating charges | 640/8 | €387 | €404 | +€17 | +4.4% |
| Gross operating margin | 9900 | €18,778 | €12,693 | -€6,085 | -32.4% |
| Operating profit (loss) | 9901 | €18,391 | €12,289 | -€6,102 | -33.2% |
| Financial charges | 65/66B | €86 | €58 | -€28 | -32.6% |
| Recurring financial charges | 65 | €86 | €58 | -€28 | -32.6% |
| Profit (loss) for the period before taxes | 9903 | €18,305 | €12,231 | -€6,074 | -33.2% |
| Profit (loss) for the period | 9904 | €18,305 | €12,231 | -€6,074 | -33.2% |
| Profit (loss) for the period to be appropriated | 9905 | €18,305 | €12,231 | -€6,074 | -33.2% |
Source: filed annual accounts (NBB), financial years ended 31 March 2025 and 31 March 2026. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 16 October 2026 via checked.be.